Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection

Mark A. Jacobson, David Yajko, Donald W Northfelt, Edwin Charlebois, David Gary, Carol Brosgart, Cynthia A. Sanders, W. Keith Hadley

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Patients with AIDS and disseminated Mycobacterium avium complex (MAC) infection received rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg) or matching placebos daily for 8 weeks. Patients were monitored every 2 weeks clinically and by quantitating MAC colony-forming units (cfu) per milliliter of blood. Analysis of baseline characteristics revealed no significant differences between groups. After 8 weeks, MAC cfu had decreased by ≥1 log/mL in 4 of 9 treated patients versus 0 of 10 placebo recipients while increasing by ≥1 log/mL in 1 and 7, respectively (P = .006). While the average combined clinical response score declined in both groups, it tended to decrease less in treated patients (P = .36). On the other hand, dose-limiting toxicity (primarily nausea and adverse drug interactions) occurred in 9 of 12 treatment versus 1 of 12 placebo patients (P = .005). Combined rifabutin-ethambutol-ciprofloxacin therapy for disseminated MAC infection had significant microbiologic efficacy with some evidence of clinical efficacy but was associated with drug intolerance.

Original languageEnglish (US)
Pages (from-to)112-119
Number of pages8
JournalJournal of Infectious Diseases
Volume168
Issue number1
StatePublished - Jul 1993
Externally publishedYes

Fingerprint

Mycobacterium avium Complex
Ethambutol
Rifampin
Ciprofloxacin
Acquired Immunodeficiency Syndrome
Randomized Controlled Trials
Placebos
Infection
Stem Cells
Rifabutin
Drug Interactions
Nausea
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. / Jacobson, Mark A.; Yajko, David; Northfelt, Donald W; Charlebois, Edwin; Gary, David; Brosgart, Carol; Sanders, Cynthia A.; Hadley, W. Keith.

In: Journal of Infectious Diseases, Vol. 168, No. 1, 07.1993, p. 112-119.

Research output: Contribution to journalArticle

Jacobson, Mark A. ; Yajko, David ; Northfelt, Donald W ; Charlebois, Edwin ; Gary, David ; Brosgart, Carol ; Sanders, Cynthia A. ; Hadley, W. Keith. / Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. In: Journal of Infectious Diseases. 1993 ; Vol. 168, No. 1. pp. 112-119.
@article{cf7d78df38d74c3792ffc4415f55e345,
title = "Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection",
abstract = "Patients with AIDS and disseminated Mycobacterium avium complex (MAC) infection received rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg) or matching placebos daily for 8 weeks. Patients were monitored every 2 weeks clinically and by quantitating MAC colony-forming units (cfu) per milliliter of blood. Analysis of baseline characteristics revealed no significant differences between groups. After 8 weeks, MAC cfu had decreased by ≥1 log/mL in 4 of 9 treated patients versus 0 of 10 placebo recipients while increasing by ≥1 log/mL in 1 and 7, respectively (P = .006). While the average combined clinical response score declined in both groups, it tended to decrease less in treated patients (P = .36). On the other hand, dose-limiting toxicity (primarily nausea and adverse drug interactions) occurred in 9 of 12 treatment versus 1 of 12 placebo patients (P = .005). Combined rifabutin-ethambutol-ciprofloxacin therapy for disseminated MAC infection had significant microbiologic efficacy with some evidence of clinical efficacy but was associated with drug intolerance.",
author = "Jacobson, {Mark A.} and David Yajko and Northfelt, {Donald W} and Edwin Charlebois and David Gary and Carol Brosgart and Sanders, {Cynthia A.} and Hadley, {W. Keith}",
year = "1993",
month = "7",
language = "English (US)",
volume = "168",
pages = "112--119",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection

AU - Jacobson, Mark A.

AU - Yajko, David

AU - Northfelt, Donald W

AU - Charlebois, Edwin

AU - Gary, David

AU - Brosgart, Carol

AU - Sanders, Cynthia A.

AU - Hadley, W. Keith

PY - 1993/7

Y1 - 1993/7

N2 - Patients with AIDS and disseminated Mycobacterium avium complex (MAC) infection received rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg) or matching placebos daily for 8 weeks. Patients were monitored every 2 weeks clinically and by quantitating MAC colony-forming units (cfu) per milliliter of blood. Analysis of baseline characteristics revealed no significant differences between groups. After 8 weeks, MAC cfu had decreased by ≥1 log/mL in 4 of 9 treated patients versus 0 of 10 placebo recipients while increasing by ≥1 log/mL in 1 and 7, respectively (P = .006). While the average combined clinical response score declined in both groups, it tended to decrease less in treated patients (P = .36). On the other hand, dose-limiting toxicity (primarily nausea and adverse drug interactions) occurred in 9 of 12 treatment versus 1 of 12 placebo patients (P = .005). Combined rifabutin-ethambutol-ciprofloxacin therapy for disseminated MAC infection had significant microbiologic efficacy with some evidence of clinical efficacy but was associated with drug intolerance.

AB - Patients with AIDS and disseminated Mycobacterium avium complex (MAC) infection received rifampin (600 mg) plus ethambutol (25 mg/kg) plus ciprofloxacin (750 mg) or matching placebos daily for 8 weeks. Patients were monitored every 2 weeks clinically and by quantitating MAC colony-forming units (cfu) per milliliter of blood. Analysis of baseline characteristics revealed no significant differences between groups. After 8 weeks, MAC cfu had decreased by ≥1 log/mL in 4 of 9 treated patients versus 0 of 10 placebo recipients while increasing by ≥1 log/mL in 1 and 7, respectively (P = .006). While the average combined clinical response score declined in both groups, it tended to decrease less in treated patients (P = .36). On the other hand, dose-limiting toxicity (primarily nausea and adverse drug interactions) occurred in 9 of 12 treatment versus 1 of 12 placebo patients (P = .005). Combined rifabutin-ethambutol-ciprofloxacin therapy for disseminated MAC infection had significant microbiologic efficacy with some evidence of clinical efficacy but was associated with drug intolerance.

UR - http://www.scopus.com/inward/record.url?scp=0027159457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027159457&partnerID=8YFLogxK

M3 - Article

C2 - 8515098

AN - SCOPUS:0027159457

VL - 168

SP - 112

EP - 119

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -